STOCK PURCHASE WARRANTSecurities Purchase Agreement • April 16th, 2018 • Adial Pharmaceuticals, Inc. • Pharmaceutical preparations • Delaware
THIS CERTIFIES THAT, for value received, ___________________ (“Holder”) or its assigns, is entitled to purchase from Adial Pharmaceuticals, Inc., a Delaware corporation (the “Company”), at any time or from time to time during the period specified in Paragraph 2 hereof and subject to adjustment as provided herein, _________ fully paid and nonassessable shares of the Company’s Common Stock, par value $0.001 per share (the “Common Stock”), at an exercise price per share equal to $________ per share of Common Stock (the “Exercise Price”). The term “Warrant Shares,” as used herein, refers to the shares of Common Stock purchasable hereunder. The Warrant Shares and the Exercise Price are subject to adjustment as provided in Paragraph 4 hereof. The term “Warrant” means this Stock Purchase Warrant issued pursuant to that certain Securities Purchase Agreement, dated ___________ __, 2018, by and among the Company and the Investor listed on the execution page thereof (the “Securities Purchase Agre
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • April 16th, 2018 • Adial Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
SECURITIES PURCHASE AGREEMENT (this “Agreement”), dated as of __________, 2018, by and between Adial Pharmaceuticals, Inc., a Delaware corporation, with headquarters located at 1180 Seminole Trail, Charlottesville, Virginia 22901 (the “Company”), and ____________ with an address at _________________________________ (the “Investor”).
SECURITY AGREEMENTSecurity Agreement • April 16th, 2018 • Adial Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
SECURITY AGREEMENT (this “Agreement”), dated as of __________, 2018, by and between Adial Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and the secured parties signatory hereto and their respective endorsees, transferees and assigns (collectively, the “Secured Parties” and each, a “Secured Party”).
AMENDMENT #5 TO LICENSE AGREEMENTLicense Agreement • April 16th, 2018 • Adial Pharmaceuticals, Inc. • Pharmaceutical preparations
This Amendment #5, dated as of December 14, 2017 (this “Agreement”), to the License Agreement (as defined below) is by and between the University of Virginia Patent Foundation d/b/a the University of Virginia Licensing and Ventures Group, a Virginia not-for-profit corporation of the Commonwealth of Virginia, having its principal offices at 1180 Seminole Tr., Suite 495, Charlottesville, VA 29901 (“UVA LVG”), and Adial Pharmaceuticals, Inc, a Delaware corporation (f/k/a ADial Pharmaceuticals, LLC) (“Adial” and together with “UVA LVG”, the “Parties”).
BACKSTOP COMMITMENT AGREEMENTBackstop Commitment Agreement • April 16th, 2018 • Adial Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
BACKSTOP COMMITMENT AGREEMENT (this “Agreement”), dated as of February 22, 2018, by and among Adial Pharmaceuticals, Inc., a company organized under the laws of the state of Delaware, (the “Company”) and MVA 151 Investors LLC, a Virginia limited liability company, (the “Backstop Investor”; and together with the Company, the “Parties” and each a “Party”).
SETTLEMENT AGREEMENTSettlement Agreement • April 16th, 2018 • Adial Pharmaceuticals, Inc. • Pharmaceutical preparations
This Settlement Agreement (the “Agreement”) dated as of February 22, 2018 is made by and between Adial Pharmaceuticals, Inc., a Delaware corporation, successor-in-interest to Adial Pharmaceuticals, LLC, a Virginia limited liability company (the “Company”), and FirstFire Global Opportunities Fund LLC, a Delaware limited liability company (“FirstFire”). The Company and FirstFire are collectively referred to herein as the “Parties” or each of them individually as a “Party.”
PERFORMANCE BONUS PLAN CANCELATION AGREEMENTPerformance Bonus Plan Cancelation Agreement • April 16th, 2018 • Adial Pharmaceuticals, Inc. • Pharmaceutical preparations
This Performance Bonus Plan Cancelation Agreement (this “Agreement”) is entered into as of April 1, 2018 (the “Effective Date”), by the undersigned for the benefit of Adial Pharmaceuticals, Inc. (“Adial”), a Delaware corporation.
MEDICAL TRANSLATION SERVICES AGREEMENTMedical Translation Services Agreement • April 16th, 2018 • Adial Pharmaceuticals, Inc. • Pharmaceutical preparations • Virginia
This Medical Translation Services Agreement (“Agreement”) is entered into this 29th day of January, 2018 (the “Effective Date”), by and between Medico-Trans Company, LLC (“MTC”), a Texas limited liability company, and Adial Pharmaceuticals, Inc. (“Adial”), a Delaware corporation.
